Sionna Therapeutics Reports First Quarter 2026 Financial Results
Rhea-AI Summary
Sionna Therapeutics (Nasdaq:SION) reported Q1 2026 results and CF pipeline progress. Enrollment in the PreciSION CF Phase 2a trial of SION-719 is complete, and a Phase 1 dual-combination trial of SION-451 is ongoing, with topline data for both expected in summer 2026.
Q1 2026 R&D expenses were $19.0M, G&A expenses $10.6M, and net loss $26.8M. Cash, cash equivalents and marketable securities totaled $289.9M at March 31, 2026, expected to fund operations into 2028.
AI-generated analysis. Not financial advice.
Positive
- Enrollment completed in Phase 2a PreciSION CF trial of SION-719
- Phase 1 dual-combination trial of SION-451 on track for summer 2026 data
- Two clinical-stage NBD1 stabilizer programs with expected topline readouts in summer 2026
- Cash, cash equivalents and marketable securities of $289.9M as of March 31, 2026
- Cash runway expected to fund operations into 2028
Negative
- R&D expenses increased to $19.0M from $13.7M year over year
- G&A expenses increased to $10.6M from $6.0M year over year
- Net loss widened to $26.8M from $16.5M in the prior-year quarter
News Market Reaction – SION
On the day this news was published, SION declined 10.90%, reflecting a significant negative market reaction. Argus tracked a trough of -7.4% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $243M from the company's valuation, bringing the market cap to $1.99B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SION was up 3.89% while Argus momentum peers like LENZ (-12.31%) and UPB (-3.84%) were moving down, indicating stock-specific strength versus weaker biotech peers.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 02 | Q4/FY 2025 results | Neutral | -7.2% | Reported FY 2025 results, cash $310.3M, trials on track into mid-2026. |
| Nov 05 | Q3 2025 results | Positive | -1.6% | Q3 results with Phase 2a and dual-combo trials initiated and cash $325.0M. |
| Aug 11 | Q2 2025 results | Positive | +13.4% | Q2 results plus positive Phase 1 NBD1 stabilizer data and cash $337.3M. |
| May 12 | Q1 2025 results | Positive | +4.7% | Q1 2025 results, post-IPO cash $354.7M and clear CF milestones outlined. |
| Mar 20 | Q4/FY 2024 results | Positive | +0.0% | Q4/FY 2024 results showing pipeline progress and IPO proceeds of $219M. |
Earnings updates often highlighted strong cash runway and CF pipeline progress, with mostly constructive or muted price reactions and one notable positive spike.
Across prior earnings since March 2024, Sionna consistently emphasized advancement of its NBD1 stabilizer platform and a cash runway funded into 2028, supported by an upsized IPO raising $219M and cash balances between $325.0M and $337.3M. Earlier results paired growing R&D spend and net losses with clear clinical milestones, including Phase 1 data and initiation of Phase 2a and dual-combination trials. Today’s Q1 2026 release extends that narrative with completed Phase 2a enrollment and Phase 1 combination progress plus a still-strong cash position.
Historical Comparison
Prior earnings and financial updates produced an average move of 1.87%, typically pairing larger R&D spend with a long cash runway and steady CF pipeline milestones.
Earnings releases have tracked Sionna’s CF strategy from early Phase 1 NBD1 stabilizer data through initiation of Phase 2a and dual-combination studies, while maintaining cash expected to fund operations into 2028.
Regulatory & Risk Context
An effective Form S-3ASR filed on March 2, 2026 registers up to $250,000,000 of securities, including an at-the-market program with Leerink Partners. Usage count is 0, so no sales have been taken down from this shelf yet.
Market Pulse Summary
The stock dropped -10.9% in the session following this news. A negative reaction despite operational progress would contrast with the company’s emphasis on a solid cash balance of $289.9M and funding into 2028. The market may focus on higher R&D and G&A expenses and a larger Q1 2026 net loss of $26.8M versus $16.5M a year earlier. An effective $250M S-3ASR ATM facility also provides issuance capacity, which can pressure sentiment around future dilution.
Key Terms
phase 2a medical
proof-of-concept medical
pharmacokinetics medical
cftr medical
nbd1 stabilizer medical
AI-generated analysis. Not financial advice.
Enrollment completed in the PreciSION CF Phase 2a proof-of-concept trial evaluating NBD1 stabilizer SION-719 as an add-on to standard of care in participants with cystic fibrosis; topline data on track for the summer of 2026
Ongoing Phase 1 trial evaluating NBD1 stabilizer SION-451 in proprietary dual combinations with SION-2222 and with SION-109 in healthy volunteers is also on track for topline data in the summer of 2026
Maintained strong cash position with approximately
WALTHAM, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
“We entered 2026 with strong execution across our programs, highlighted by the recent completion of enrollment in our proof-of-concept Phase 2a trial of SION-719, an important milestone for Sionna,” said Mike Cloonan, President and Chief Executive Officer of Sionna. “With both of our clinical stage NBD1 stabilizer programs on track for topline readouts this summer, we remain focused on advancing these first-in-class product candidates that could expand therapeutic options for people with CF.”
Pipeline Updates
NBD1 Stabilizers
- Enrollment Completed in PreciSION CF Phase 2a Proof-of-Concept Trial with SION-719; Topline Data On Track: In April 2026, Sionna announced it had completed enrollment in the PreciSION CF Phase 2a proof-of-concept (POC) trial (NCT07108153) evaluating SION-719 as an add-on to standard of care (SOC) in CF patients. The trial is evaluating the safety, tolerability, and pharmacokinetics (PK) of SION-719 when administered with SOC and assessing change in CFTR function as measured by sweat chloride levels. Topline data from this trial are anticipated in the summer of this year.
- Ongoing Phase 1 Dual Combination Trial with SION-451 and Complementary Modulators; Topline Data On Track: The Phase 1 trial (NCT07035990) is evaluating SION-451 in proprietary dual combinations with SION-2222 (galicaftor), a transmembrane domain 1 (TMD1)-directed CFTR corrector, and with SION-109, an intracellular loop 4 (ICL4)-directed CFTR corrector, in healthy volunteers. Topline data from this trial are anticipated in the summer of this year.
- Encore Data to be Presented at 49th European Cystic Fibrosis Conference: Encore data previously presented at the 2025 North American Cystic Fibrosis Conference (NACFC) will be featured in an oral and ePoster presentation at the European Cystic Fibrosis Society’s (ECFS) 49th European Cystic Fibrosis Conference, being held June 3-6, 2026, in Lisbon, Portugal.
Details of the presentations are as follows:
Abstract Title: Safety, tolerability, and pharmacokinetics of novel NBD1 stabilizers SION-719 and SION-451 from two Phase 1 first-in-human studies
Abstract number: EPS07.01
Presenting Author: Jason H. Maley, MD, MS, Senior Director, Clinical Development, Sionna Therapeutics
Oral ePoster Session Title: Old and new – exploring the portfolio for CF treatment
Date and Time: Friday, June 5, 2026, 2:00-2:06 p.m. CEST/9:00-9:06 a.m. ET
Abstract Title: Clinical-stage NBD1 stabilizers can increase F508del-CFTR protein half-life to wild-type levels when used alone or in combination with other CFTR modulators
Abstract ID: WS15.3
Presenting Author: Greg Hurlbut, Ph.D., Co-Founder and Senior Vice President, Discovery Research, Sionna Therapeutics
Session Title: Workshop 15: Novel approaches, future therapies
Date and Time: Friday, June 5, 2026, 5:30-5:45 p.m. CEST/11:30-11:45 a.m. ET
Financial Results for the Quarter Ended March 31, 2026
Research and Development Expenses: Research and development expenses were
General and Administrative Expenses: General and administrative expenses were
Net Loss: Net loss was
Cash and Cash Equivalents: Cash, cash equivalents and marketable securities totaled
About Sionna Therapeutics
Sionna Therapeutics is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Sionna’s goal is to deliver differentiated medicines for people living with CF that can restore their CFTR function to as close to normal as possible by directly stabilizing CFTR’s nucleotide binding domain 1 (NBD1), which Sionna believes is central to potentially unlocking dramatic improvements in clinical outcomes and quality of life for people with CF. Leveraging more than a decade of the co-founders’ research on NBD1, Sionna is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which occurs in NBD1. Sionna is also developing a portfolio of complementary CFTR modulators that are designed to work synergistically with its NBD1 stabilizers to improve CFTR function. For more information about Sionna, visit www.sionnatx.com.
Sionna intends to use its Investor Relations website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor Sionna’s Investor Relations website, in addition to following Sionna’s press releases, SEC filings, public conference calls, presentations, and webcasts.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Sionna’s beliefs and expectations regarding: its goal of transforming the treatment paradigm for CF and providing clinically meaningful benefit for CF patients; the potential of Sionna’s product candidates to expand therapeutic options for people with CF; the initiation, timing, progress and results of Sionna’s research and development programs, clinical trials and studies, including the timing of topline data from Sionna’s Phase 2a proof-of-concept trial and Phase 1 dual combination trial; the ability of clinical trials to demonstrate safety and efficacy of Sionna’s product candidates; the ability of Sionna’s preclinical studies or earlier clinical trials to predict later clinical trial results; and financial projections and expectations regarding the time period in which Sionna’s capital resources will be sufficient to fund its anticipated operations, including cash runway, use of capital, expenses and other financial results. In some cases, the forward-looking statements can be identified by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties inherent in the development of product candidates, including uncertainties concerning the initiation, timing, progress, and results of Sionna’s ongoing, planned and future clinical trials and studies; the Company’s ability to replicate positive results from earlier preclinical studies or clinical trials in current or future clinical trials; Sionna’s ability to demonstrate that its NBD1 stabilizers, complementary CFTR modulators, and any potential future product candidates are safe and effective for their proposed indications; regulatory developments in the United States and foreign countries; and general economic, industry and market conditions. These risks and uncertainties are described in the section entitled “Risk Factors” in Sionna’s most recent Annual Report on Form 10-K as well as any subsequent filings with the Securities and Exchange Commission. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. In addition, any forward-looking statements represent Sionna’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Sionna explicitly disclaims any obligation to update any forward-looking statements except as required by law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact
Sarah Spencer
media@sionnatx.com
Investor Contact
Juliet Labadorf
ir@sionnatx.com
| Sionna Therapeutics, Inc. Consolidated Statements of Operations (In thousands, except per share data) (unaudited) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2026 | 2025 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 18,963 | $ | 13,668 | ||||
| General and administrative | 10,636 | 5,991 | ||||||
| Total operating expenses | 29,599 | 19,659 | ||||||
| Loss from operations | (29,599 | ) | (19,659 | ) | ||||
| Other income: | ||||||||
| Interest income | 2,820 | 3,000 | ||||||
| Other income | - | 177 | ||||||
| Total other income | 2,820 | 3,177 | ||||||
| Net loss | $ | (26,779 | ) | $ | (16,482 | ) | ||
| Net loss per share, basic and diluted | $ | (0.60 | ) | $ | (0.62 | ) | ||
| Weighted-average common shares outstanding, basic and diluted | 44,921,984 | 26,596,059 | ||||||
| Sionna Therapeutics, Inc. Selected Consolidated Balance Sheet Data (In thousands) (Unaudited) | ||||||||
| March 31, | December 31, | |||||||
| 2026 | 2025 | |||||||
| Cash, cash equivalents, and marketable securities | $ | 289,931 | $ | 310,302 | ||||
| Working capital1 | 211,183 | 229,707 | ||||||
| Total assets | 305,039 | 325,953 | ||||||
| Total stockholders’ equity | 288,208 | 306,833 | ||||||
| 1Sionna defines working capital as current assets minus current liabilities. | ||||||||
